临床试验进展 - 公司在2024年第二季度报告了VK2735用于治疗肥胖的积极临床结果,计划将其推进至III期临床试验[7,8,9,10,11] - 公司正在开发VK2735的口服制剂,并计划于2024年第四季度启动II期临床试验[12,13,14,15,16,17] - 公司报告了VK2809在NASH和肝纤维化治疗中的积极52周组织学数据,主要和次要终点均已成功达成,安全性和耐受性良好[18,19,20,21,22,23,24,25] - 公司完成了VK0214用于X-ALD的I期临床试验入组,预计于2024年下半年公布结果[26,27,28] - 公司在美国糖尿病协会年会上报告了新型内部开发的双胰岛素素和降钙素受体激动剂(DACRA)的积极临床前数据,计划于2025年提交IND申请[29,30,31,32] 财务情况 - 研发费用增加主要是由于制造公司药物候选物、临床试验、临前试验、薪酬福利和股票激励等相关费用增加[39][40] - 一般及行政费用增加主要是由于股票激励和第三方顾问服务费用增加,部分被法律和专利服务费用减少所抵消[41] - 2024年上半年净亏损为4960万美元,较2023年同期增加,主要是由于研发费用和一般及行政费用的增加,部分被利息收入增加所抵消[42] - 截至2024年6月30日,公司持有9.42亿美元的现金、现金等价物和短期投资,较2023年12月31日的3.62亿美元大幅增加[43] 其他 - 公司将于2024年7月31日举行二季度财报电话会议[44]

Conference call scheduled for 4:30 p.m. ET todayVK2735 to Advance to Phase 3 for Obesity; End-of-Phase 2 Meeting Planned for 2H24Oral VK2735 Phase 2 Study in Obesity Expected to Begin 4Q24Positive Biopsy Results From VK2809 Reported in June; End-of-Phase 2 Meeting in NASH/MASH Planned for 4Q24Enrollment Completed in Phase 1b Study of VK0214 for X-ALD; Data Expected 2H24In Vivo Data From Novel Amylin Agonist Program Reported at ADA in June; IND in Obesity Planned for 2025SAN DIEGO, July 24, 2024 /PRNewswire/ ...

wragg VKTX's Investment Thesis Is Promising, Made Possible By The GLP-1 Hype We previously covered Novo Nordisk (NVO) and Eli Lilly and Company (LLY) discussing their prospects and pipelines attributed to the market exuberance surrounding GLP-1 therapies. For this particular article, we will be looking at Viking Therapeutics, Inc. (NASDAQ:NASDAQ:VKTX) and sharing our findings about the stock, continuing the theme surrounding obesity therapies. VKTX Pipeline VKTXFor the uninitiated, VKTX is a pre-revenue ...

Viking Therapeutics (VKTX) will report its second-quarter earnings on Jul 24, after market closes. Since the company lacks a marketed drug in its portfolio, we do not expect any revenues. The Zacks Consensus Estimate for earnings is pegged at a loss of 26 cents per share.Viking’s loss estimates have increased from $1.08 per share to $1.11 for 2024 and from $1.42 to $1.45 for 2025 in the past 60 days. Image Source: Zacks Investment ResearchEarnings Surprise HistoryThe biotech firm’s performance has been mixe ...

This biotech stock fits the profile of a potentially big winner to a T.Fortunes have been made on biotech stocks over the last few decades. The secret to success has been to invest in an up-and-coming biotech company before it even had a product on the market. Ideally, the company would have a pipeline featuring multiple promising candidates with significant commercial potential.Viking Therapeutics (VKTX 0.52%) fits the profile of such a stock to a T. Could Viking be a millionaire-maker?What's in Viking The ...

Viking Therapeutics, Inc. (VKTX) closed the latest trading day at $50.12, indicating a +0.56% change from the previous session's end. The stock's performance was ahead of the S&P 500's daily loss of 0.78%. At the same time, the Dow lost 1.29%, and the tech-heavy Nasdaq lost 0.7%.The company's stock has dropped by 1.58% in the past month, falling short of the Medical sector's gain of 2.23% and the S&P 500's gain of 2.14%.Market participants will be closely following the financial results of Viking Therapeuti ...

Conference Call Scheduled for Wednesday, July 24 at 4:30 p.m. Eastern Time SAN DIEGO, July 17, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the second quarter 2024 after the market close on Wednesday, July 24, 2024.The company will host a conference call to discuss financial results and ...

Let's look beyond the hype the company is generating this year.Could 2024 be a breakout year for Viking Therapeutics (VKTX -4.01%)? The mid-cap biotech has generated more positive headlines than most of its peers. Excitement is through the roof. Due to crucial clinical progress, Viking Therapeutics' shares have tripled this year.Biotech investors have noticed, but many remain on the sidelines wondering whether Viking is the right choice for them -- or whether the stock is a one-hit (or one-year) wonder. Let ...

Viking's stock has tripled in less than a year, and its red-hot valuation could have investors thinking twice about buying it today.Viking Therapeutics (VKTX 7.09%) has been one of the hottest healthcare stocks to own this year, thanks to hype and excitement relating to its promising weight loss treatment, VK2735. The potential that investors see in the drug is a key reason the stock has ballooned to a market cap of nearly $6 billion despite the company generating no revenue and having no approved products ...

Sasha Brazhnik/iStock via Getty Images The weight loss drug sector is seeing an increasingly intensified drug development focus, causing a small player like Viking Therapeutics, Inc. (NASDAQ:VKTX) to slip. The small biotech has had some promising drug results, but the fear is the need to find a partner for GLP-1 manufacturing while additional drugs on the market could lead to pricing compression. My investment thesis is Bullish on Viking Therapeutics, especially with the gap closed down at $40. Source: Finv ...